MARKET

DRNA

DRNA

Dicerna
NASDAQ

Real-time Quotes | Nasdaq Last Sale

22.86
+0.03
+0.13%
After Hours: 22.86 0 0.00% 16:00 11/23 EST
OPEN
23.00
PREV CLOSE
22.83
HIGH
23.36
LOW
22.57
VOLUME
320.11K
TURNOVER
--
52 WEEK HIGH
27.68
52 WEEK LOW
11.75
MARKET CAP
1.72B
P/E (TTM)
-14.2120
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Dicerna/Roche's hepatitis B candidate shows durable effect in early-stage study
Dicerna Pharmaceuticals ([[DRNA]] -2.8%) has announced additional data from Phase 1 trial evaluating GalXC RNAi therapeutic RG6346, under development in collaboration with Roche for the treatment of chronic hepatitis B virus ((HBV)) infection. Data
Seekingalpha · 11/16 18:17
Dicerna earns $10M in milestone from Eli Lilly
FDA has signed-off investigational new drug application ((IND)) filed by Eli Lilly ([[LLY]] +0.3%) for LY3561774, the first candidate to emerge from licensing collaboration between Dicerna ([[DRNA]] -3.8%), and Eli Lilly.The
Seekingalpha · 11/16 16:31
Dicerna Announces FDA Acceptance of Lilly's Investigational New Drug Application For First GalXC RNAi Candidate Under Companies' Global Research Collaboration And Licensing Agreement, Triggering $10M Payment To Dicerna
— Milestone Achievement Reflects First Investigational Candidate to Emerge Under Multi-Target Collaboration and Triggers $10 Million Payment to Dicerna — – Lilly Targeting Initiation of Phase 1
Benzinga · 11/16 12:31
Dicerna Announces Positive Updated Data From Phase 1 Trial of RG6346 for Treatment of Chronic Hepatitis B Virus (HBV) Infection at AASLDs The Liver Meeting® Digital Experience 2020
Dicerna announced positive updated Phase 1 data on its investigational GalXC™ RNAi therapeutic for the treatment of chronic hepatitis B virus (HBV).
Business Wire · 11/16 12:31
The Week Ahead In Biotech: The Vaccine Updates, Drug Presentations, And FDA Decisions That Will Move The Markets
Biotech stocks advanced in the week ended Nov. 13 amid a vaccine news flow-induced rally that also lifted the broader market.
Benzinga · 11/15 15:14
Dicerna Pharmaceuticals EPS misses by $0.05, misses on revenue
Dicerna Pharmaceuticals (DRNA): Q3 GAAP EPS of -$0.29 misses by $0.05.Revenue of $48.9M (+508.2% Y/Y) misses by $2.81M.Press Release
Seekingalpha · 11/05 22:09
Dicerna Pharmaceuticals Q3 EPS $(0.29) Misses $(0.20) Estimate, Sales $48.88M Miss $51.50M Estimate
Dicerna Pharmaceuticals (NASDAQ:DRNA) reported quarterly losses of $(0.29) per share which missed the analyst consensus estimate of $(0.20) by 45 percent. This is a 35.56 percent increase over losses of $(0.45) per share
Benzinga · 11/05 22:04
Dicerna Pharmaceuticals, Inc. to Host Earnings Call
ACCESSWIRE · 11/05 19:30
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of DRNA. Analyze the recent business situations of Dicerna through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 11 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average DRNA stock price target is 35.33 with a high estimate of 48.00 and a low estimate of 25.00.
EPS
Institutional Holdings
Institutions: 255
Institutional Holdings: 70.10M
% Owned: 93.41%
Shares Outstanding: 75.04M
TypeInstitutionsShares
Increased
67
4.21M
New
54
-2.89M
Decreased
53
3.07M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.80%
Pharmaceuticals & Medical Research
-0.36%
Key Executives
Chairman/Independent Director
J. Kevin Buchi
President/Chief Executive Officer/Director
Douglas Fambrough
Chief Financial Officer
Douglas Pagan
Chief Operating Officer/Executive Vice President
James Weissman
Executive Vice President/Chief Scientific Officer
Bob Brown
Senior Vice President/Director of Human Resources
Regina Paglia
Vice President
Hardean Achneck
Executive Vice President
Shreeram Aradhye
Vice President
Steven Kates
Other
Robert Ciappenelli
Other
David Caponera
Secretary
Ling Zeng
Other
Rob Ciappenelli
Independent Director
Stephen Doberstein
Independent Director
Martin Freed
Other
Rebecca Peterson
Independent Director
Patrick Gray
Independent Director
Stephen Hoffman
Independent Director
.. ..
Independent Director
Adam Koppel
Independent Director
Marc Kozin
Independent Director
Anna Protopapas
Independent Director
Cynthia Smith
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About DRNA
Dicerna Pharmaceuticals, Inc. is a ribonucleic acid (RNA) interference-based biopharmaceutical company. The Company operates in the segment of discovery, research and development of treatments based on its RNA interference (RNAi) technology platform. It is focused on development of RNAi-based therapeutics using its GalXC RNAi platform for the treatment of diseases involving the liver, including rare diseases, viral infectious diseases, chronic liver diseases and cardiovascular diseases. Its development programs include dacryocystorhinostomy (DCR)-PHXC for the treatment of primary hyperoxaluria (PH), which is in a Phase I clinical trial; DCR-HBVS for the treatment of chronic hepatitis B virus (HBV), which is in a Phase I clinical trial, and a product candidate against a rare liver disease. It also developed a wholly owned clinical candidate, DCR-BCAT, targeting the β-catenin oncogene. DCR-BCAT is delivered by its lipid nanoparticle (LNP) tumor delivery system, EnCore.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Dicerna Pharmaceuticals Inc stock information, including NASDAQ:DRNA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, DRNA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading DRNA stock methods without spending real money on the virtual paper trading platform.